ClinicalTrials.gg

Program

apitegromab

Also written as “Apitegromab” and “SRK-015”.

Its studies are mostly in Spinal Muscular Atrophies of Childhood · Muscular Dystrophy, Facioscapulohumeral · Obesity, led by Scholar Rock.

Furthest: phase 3, since Dec 1, 20216 company-led studies, 3 open or runningNext primary completion: Jun 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Scholar Rock63 open or runningphase 3since Dec 1, 2021Apr 16, 2019Jun 2028phase 2 · NCT07435129

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2019First study: phase 2 study in Muscular Atrophy, SpinalFirst studyNCT03921528 · 58 enrolled · United States, Italy, Netherlands and more
  2. Dec 1, 2021Phase 3 study in Muscular Atrophy, SpinalNCT05156320 · 188 enrolled · United States, Belgium, France and more
  3. Nov 7, 2022Phase 3 study in Muscular Atrophy, SpinalNCT05626855 · 238 enrolled · United States, Belgium, France and more
  4. May 22, 2024Phase 2 study in OverweightNCT06445075 · 102 enrolled · United States
  5. Apr 16, 2025Phase 2 study in Muscular Atrophy, SpinalNCT07047144 · 52 planned · United States, Belgium, France and more
  6. Feb 10, 2026Phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT07435129 · 60 planned · United States

Ahead

  1. Nov 1, 2026Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT05626855
  2. Jun 2028Primary completion: phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT07435129
  3. Nov 2028Primary completion: phase 2 study in Muscular Atrophy, SpinalNCT07047144

TargetBeta

MSTN →read by rule
“Growth/differentiation factor 8 inhibitor”ChEMBL 37, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07435129Muscular Dystrophy, Facioscapulohumeral · United States2RecruitingJun 202860
NCT07047144Muscular Atrophy, Spinal · United States, Belgium, France and more2RecruitingNov 202852
NCT06445075Overweight · United States2CompletedMar 4, 2025102
NCT05626855Muscular Atrophy, Spinal · United States, Belgium, France and more3Active, not recruitingNov 1, 2026238
NCT05156320Muscular Atrophy, Spinal · United States, Belgium, France and more3CompletedDec 18, 2024188
NCT03921528Muscular Atrophy, Spinal · United States, Italy, Netherlands and more2CompletedJan 19, 202158

How it is read

Names in the registry

  • “Apitegromab”, 5 entries
  • “SRK-015”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.